首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   193893篇
  免费   19007篇
  国内免费   8235篇
耳鼻咽喉   2437篇
儿科学   4439篇
妇产科学   2103篇
基础医学   38820篇
口腔科学   5698篇
临床医学   14771篇
内科学   27390篇
皮肤病学   5114篇
神经病学   10389篇
特种医学   5934篇
外国民族医学   125篇
外科学   16340篇
综合类   29027篇
现状与发展   56篇
预防医学   5680篇
眼科学   3730篇
药学   14780篇
  31篇
中国医学   5992篇
肿瘤学   28279篇
  2024年   148篇
  2023年   2744篇
  2022年   3485篇
  2021年   6605篇
  2020年   6360篇
  2019年   6470篇
  2018年   6699篇
  2017年   6805篇
  2016年   7090篇
  2015年   8000篇
  2014年   11709篇
  2013年   13002篇
  2012年   11131篇
  2011年   12549篇
  2010年   10312篇
  2009年   9937篇
  2008年   10344篇
  2007年   10484篇
  2006年   9475篇
  2005年   8612篇
  2004年   7695篇
  2003年   6713篇
  2002年   5495篇
  2001年   4771篇
  2000年   3928篇
  1999年   3421篇
  1998年   2874篇
  1997年   2755篇
  1996年   2322篇
  1995年   2433篇
  1994年   2217篇
  1993年   1832篇
  1992年   1411篇
  1991年   1304篇
  1990年   1050篇
  1989年   977篇
  1988年   896篇
  1987年   707篇
  1986年   669篇
  1985年   974篇
  1984年   936篇
  1983年   650篇
  1982年   701篇
  1981年   557篇
  1980年   473篇
  1979年   391篇
  1978年   278篇
  1977年   215篇
  1976年   201篇
  1975年   102篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
102.

Aims

Concomitant chemoradiation is the standard of care in patients with inoperable non-small cell lung cancer. The purpose of this study was to analyse the survival outcome and toxicity data of using hypofractionated chemoradiation.

Materials and methods

One hundred patients were treated from June 2011 to November 2016. Treatment consisted of 55 Gy in 20 daily fractions concurrently with split-dose cisplatin vinorelbine chemotherapy over 4 weeks followed by two cycles of cisplatin vinorelbine only. Survival was estimated using Kaplan–Meier and Cox regression was carried out for known prognostic factors. A systematic search of literature was conducted using Medline, Embase and Cochrane databases and relevant references included.

Results

In total, 97% of patients completed radiotherapy and 73% of patients completed all four cycles of chemotherapy. One patient died of a cardiac event during consolidative chemotherapy. There were two cases of grade 4 toxicities (one sepsis, one renal impairment). Grade 3 toxicities included nausea/vomiting (17%), oesophagitis (15%), infection with neutropenia (12%) and pneumonitis (4%). Clinical benefit was seen in 86%. Two-year progression-free survival and overall survival rates were 49% and 58%, respectively. The median progression-free survival and overall survival were 23.4 and 43.4 months, respectively. The only significant prognostic factor was the number of chemotherapy cycles received (P = 0.02). The systematic review identified 13 relevant studies; a variety of regimens were assessed with variable reporting of outcomes and toxicity but with overall an improvement in survival over time.

Conclusion

Our experience compared with the original phase II trial showed improved treatment completion rates and survival with acceptable morbidity. With appropriate patient selection this regimen is an effective treatment option for locally advanced non-small cell lung cancer. This study helps to benchmark efficacy and toxicity rates while considering the addition of new agents to hypofractionated concurrent chemoradiotherapy. The agreement of a standard regimen for assessment in future trials would be beneficial.  相似文献   
103.
目的:观察非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)患者自体造血干细胞移植(autologous hematopoietic stem cell transplantation,ASCT)术后应用重组人α-2b干扰素(α-2b IFN)进行早期干预治疗的临床疗效。方法:选取18例行ASCT的NHL患者为研究对象,移植前疾病评估均未达到完全缓解(complete remission,CR),试验组血象恢复后给予IFN 3 000 000 U次/隔日干预治疗,3个月后停用;对照组未行干扰素干预治疗,分析总体疗效及两组对比的生存情况。结果:随访中位时间为34(10~50)个月,患者中位生存时间为37(31~45)个月,3年总体无进展生存(progressive free survival,PFS)、总生存(overall survivial,OS)分别为54.7%、66.8%。ASCT后试验组1年内无疾病复发,2年内复发率为12.5%;对照组1年内复发率为20%,2年内复发率为30%。结论:NHL患者在ASCT后给予重组人α-2b IFN早期干预治疗,患者耐受性好,可能降低移植后早期复发率。  相似文献   
104.
105.
张玲  张太君  黎颖  丁伟森  熊维建  钟锦  骆言 《陕西中医》2020,(12):1751-1754
目的:探讨五色培元固本膏对维持性血液透析(MHD)患者细胞免疫功能的影响。方法:90例MHD患者随机分为对照组和治疗组,两组血透方法相同。对照组给予一般治疗及血透治疗,治疗组在对照组基础上口服五色培元固本膏,连续治疗3个月; 20例健康志愿者作为正常组,三组观察时间均为3个月。治疗前后用流式细胞技术检测各组T细胞亚群表达水平,酶联免疫吸附法检测各组白介素-2(IL-2)和可溶性白介素-2受体(sIL-2R)蛋白表达水平。结果:治疗前与正常组比较,对照组与治疗组CD4+、CD4+/CD8+和IL-2表达水平均明显下降,CD8+和sIL-2表达水平均上升,差异有统计学意义(P<0.05)。治疗后,与对照组相比较,治疗组CD4+、CD4+/CD8+、IL-2表达水平明显升高,CD8+和sIL-2表达水平均降低,差异有统计学意义(P<0.05)。治疗组相较正常组CD4+T淋巴细胞、CD4+/CD8+、IL-2表达水平,差异无统计学意义(P>0.05),CD8+、sIL-2表达水平升高。结论:五色培元固本膏调节T淋巴细胞和IL-2表达改善MHD的细胞免疫功能。  相似文献   
106.
107.
108.
G protein-coupled estrogen receptor-1 (GPER), a member of the G protein-coupled receptor (GPCR) superfamily, mediates estrogen-induced proliferation of normal and malignant breast epithelial cells. However, its role in breast cancer stem cells (BCSCs) remains unclear. Here we showed greater expression of GPER in BCSCs than non-BCSCs of three patient-derived xenografts of ER/PR+ breast cancers. GPER silencing reduced stemness features of BCSCs as reflected by reduced mammosphere forming capacity in vitro, and tumor growth in vivo with decreased BCSC populations. Comparative phosphoproteomics revealed greater GPER-mediated PKA/BAD signaling in BCSCs. Activation of GPER by its ligands, including tamoxifen (TMX), induced phosphorylation of PKA and BAD-Ser118 to sustain BCSC characteristics. Transfection with a dominant-negative mutant BAD (Ser118Ala) led to reduced cell survival. Taken together, GPER and its downstream signaling play a key role in maintaining the stemness of BCSCs, suggesting that GPER is a potential therapeutic target for eradicating BCSCs.  相似文献   
109.
Similar family-based cancer and genealogy data from Norway and Utah allowed comparisons of the incidence of testicular cancer (TC), and exploration of the role of Scandinavian ancestry and family history of TC in TC risk. Our study utilizes data from the Utah Population Database and Norwegian Population Registers. All males born during 1951–2015 were followed for TC until the age of 29 years. A total of 1,974,287 and 832,836 males were born in Norway and Utah, respectively, of whom 2,686 individuals were diagnosed with TC in Norway and 531 in Utah. The incidence per year of TC in Norway (10.6) was twice that observed in Utah (5.1) for males born in the last period (1980–1984). The incidence rates of TC in Utah did not differ according to the presence or absence of Scandinavian ancestry (p = 0.669). Having a brother diagnosed with TC was a strong risk factor for TC among children born in Norway and Utah, with HR = 9.87 (95% CI 5.68–17.16) and 6.02 (95% CI 4.80–7.55), respectively; with even higher HR observed among the subset of children in Utah with Scandinavian ancestry (HR = 12.30, 95% CI 6.78–22.31). A clear difference in TC incidence among individuals born in Norway and descendants of Scandinavian people born in Utah was observed. These differences in TC rates point to the possibility of environmental influence. Family history of TC is a strong risk factor for developing TC in both populations.  相似文献   
110.
目的探讨参附注射液对猪创伤性心脏骤停复苏后肾损伤的保护作用。方法国产健康雄性白猪21头,采用随机数字表法分为假手术组(Sham组,n=5)、创伤性心脏骤停复苏(TCA组,n=9)和参附组(SFI组,n=7)。Sham组只经历气管插管及动静脉置管,不经历放血、复苏等过程。TCA组匀速释放总血容量的40%,然后经电刺激法室颤5 min,心肺复苏5 min后常规液体复苏治疗。SFI组在TCA组基础上于复苏后5 min进行参附注射液的干预。于放血前10 min、复苏后1、3、6、24 h检测血清TNF-α、IL-6、肌酐(Cr)、尿素氮(BUN)水平。复苏后24 h经右侧耳缘静脉注射10%氯化钾液20 mL处死猪,迅速获取肾组织标本,应用原位末端标记法(TNUEL法)检测细胞凋亡情况,免疫组织化学法检测半胱氨酸天冬氨酸蛋白酶-3(Caspase-3)的蛋白表达水平。结果TCA组中有8头猪复苏成功,SFI组和Sham组中所有猪复苏成功。与Sham组比较,TCA组血清Cr水平在复苏后24 h、BUN水平在复苏后1、3、6、24 h均明显增高(均P<0.05),TNF-α、IL-6水平在复苏后3、6、24 h明显增高(均P<0.05),复苏后24 h后肾组织细胞凋亡指数及Caspase-3表达增加(均P<0.05)。与TCA组比较,SFI组BUN水平复苏后3、6 h明显降低(均P<0.05),TNF-α、IL-6水平在复苏后3、6、24 h明显降低(均P<0.05),肾组织细胞凋亡指数和Caspase-3蛋白表达有所降低,但差异无统计学意义(均P>0.05)。结论在猪TCA复苏模型中,早期应用参附注射液能够明显减轻复苏后肾损伤。其机制可能与抑制系统炎症反应、减轻细胞凋亡有关。  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号